HomecollectionsWebinarsCRISPR Protein Products

CRISPR Protein Products


What Does it Cover?

In this webinar, Yanfang Jiang discusses current CRISPR protein products focusing on the specific enzyme characteristics of each protein and their potential applications for the research community. These innovative new proteins are great additions to the researcher’s genome editing workflow. Benefit from Yangfang’s expertise in this field and learn how these new proteins can enhance your CRISPR experimental results.

Proteins discussed:

  • SpCas9 (standard genome editing and cloning applications)
  • eSpCas9 (reduced off-targets)
  • SpCas9-D10A (reduced off-targets and nicking applications)
  • dSpCas9-FLAG-biotin (targeted DNA binding / isolation)
  • FnCas9 (same PAM as SpCas9, but with 5’-4 bp overhangs for cloning large fragments)

Who Should Watch?

  • Academic, biotech, and pharma R&D teams who specialize in cellular genome editing.
  • Scientists moving beyond genome editing in live cells to apply CRISPR to the processing of purified genomic DNA (binding, detection, NGS-prep, etc.)
  • Any potential customers who might be interested in using any of the CRISPR protein products


Yanfang Jiang, Ph.D.


Senior R&D Scientist

Dr. Yanfang Jiang obtained her PhD degree in microbiology from Department of Microbiology, University of Illinois at Urbana-Champaign, in the laboratory of Dr. John E. Cronan, who is a member of the National Academy of Sciences. Her thesis work focused on lipid and fatty metabolism and fatty acid derived cofactors in bacteria. She completed her postdoctoral training in Washington University in St. Louis, worked on glucose sensing and transport in yeast S. cerevisiae with Dr. Mark Johnston in the Department of Genetics and Center for Genome Sciences. She later worked in Dr. David Wang’s laboratory in the Department of Molecular Microbiology in Washington University, involved in discovery and characterization of the first viral infection in nematodes. Dr. Jiang joined our Genome Engineering R&D Group in October 2015 and has been primarily working on developing CRISPR-Cas9 protein products.